Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Debbie Malden"'
Autor:
Joseph A. Lewnard, Parag Mahale, Debbie Malden, Vennis Hong, Bradley K. Ackerson, Bruno J. Lewin, Ruth Link-Gelles, Leora R. Feldstein, Marc Lipsitch, Sara Y. Tartof
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract The SARS-CoV-2 BA.2.86 lineage, and its sublineage JN.1 in particular, achieved widespread transmission in the US during winter 2023–24. However, this surge in infections was not accompanied by COVID-19 hospitalizations and mortality comme
Externí odkaz:
https://doaj.org/article/bfa149cc07db440b801afb35ef79d451
Autor:
Joseph A Lewnard, John M McLaughlin, Debbie Malden, Vennis Hong, Laura Puzniak, Bradley K Ackerson, Bruno J Lewin, Jeniffer S Kim, Sally F Shaw, Harpreet Takhar, Luis Jodar, Sara Y Tartof
Publikováno v:
The Lancet. Infectious diseases, vol 23, iss 7
BackgroundIn the USA, oral nirmatrelvir-ritonavir is authorised for use in patients aged 12 years or older with mild-to-moderate COVID-19 who are at risk of progression to severe disease and hospitalisation. We aimed to establish the effectiveness of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c44cf3e9facb6c38b86da6b65a9c186
https://escholarship.org/uc/item/1cp1x02k
https://escholarship.org/uc/item/1cp1x02k
Autor:
Joseph A. Lewnard, John M. McLaughlin, Debbie Malden, Vennis Hong, Laura Puzniak, Bradley K. Ackerson, Bruno J. Lewin, Jeniffer S. Kim, Sally F. Shaw, Harpreet Takhar, Luis Jodar, Sara Y. Tartof
Publikováno v:
medRxiv
BackgroundIn the United States, oral nirmatrelvir-ritonavir (Paxlovid™) is authorized for use among patients aged ≥12 years with mild-to-moderate SARS-CoV-2 infection who are at risk for progression to severe COVID-19, including hospitalization.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f87211005b63a568904df4ba80392dab
https://doi.org/10.1101/2022.10.02.22280623
https://doi.org/10.1101/2022.10.02.22280623